CONNECT BIOPHARMA HOLDINGS L (CNTB) Fundamental Analysis & Valuation

NASDAQ:CNTB • KYG235491019

Current stock price

3.03 USD
+0.1 (+3.41%)
Last:

This CNTB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CNTB Profitability Analysis

1.1 Basic Checks

  • CNTB had negative earnings in the past year.
  • In the past year CNTB has reported a negative cash flow from operations.
  • In the past 5 years CNTB always reported negative net income.
  • CNTB had a negative operating cash flow in each of the past 5 years.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M -800M -1B

1.2 Ratios

  • CNTB has a Return On Assets of -98.94%. This is in the lower half of the industry: CNTB underperforms 75.97% of its industry peers.
  • CNTB's Return On Equity of -132.16% is on the low side compared to the rest of the industry. CNTB is outperformed by 61.43% of its industry peers.
Industry RankSector Rank
ROA -98.94%
ROE -132.16%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CNTB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CNTB Health Analysis

2.1 Basic Checks

  • CNTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • CNTB has an Altman-Z score of -5.68. This is a bad value and indicates that CNTB is not financially healthy and even has some risk of bankruptcy.
  • CNTB has a Altman-Z score of -5.68. This is in the lower half of the industry: CNTB underperforms 65.89% of its industry peers.
  • CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.68
ROIC/WACCN/A
WACC9.12%
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • CNTB has a Current Ratio of 3.74. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
  • CNTB has a Current ratio of 3.74. This is comparable to the rest of the industry: CNTB outperforms 45.35% of its industry peers.
  • CNTB has a Quick Ratio of 3.74. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
  • CNTB has a Quick ratio (3.74) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CNTB Growth Analysis

3.1 Past

  • The earnings per share for CNTB have decreased strongly by -252.10% in the last year.
  • CNTB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.75%.
EPS 1Y (TTM)-252.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.8%
Revenue 1Y (TTM)-99.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, CNTB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.09% on average per year.
  • The Revenue is expected to grow by 209.21% on average over the next years. This is a very strong growth
EPS Next Y-58.23%
EPS Next 2Y-17.34%
EPS Next 3Y-26.11%
EPS Next 5Y13.09%
Revenue Next Year1569.23%
Revenue Next 2Y1500.27%
Revenue Next 3Y716.2%
Revenue Next 5Y209.21%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. CNTB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • CNTB's earnings are expected to decrease with -26.11% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.34%
EPS Next 3Y-26.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CNTB Dividend Analysis

5.1 Amount

  • No dividends for CNTB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CNTB Fundamentals: All Metrics, Ratios and Statistics

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (4/16/2026, 11:54:36 AM)

3.03

+0.1 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-18
Inst Owners49.42%
Inst Owner Change0%
Ins Owners0.69%
Ins Owner Change1.74%
Market Cap168.84M
Revenue(TTM)64.00K
Net Income(TTM)-55.48M
Analysts85.45
Price Target8.06 (166.01%)
Short Float %1.78%
Short Ratio2.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.38%
Min EPS beat(2)-32.66%
Max EPS beat(2)69.43%
EPS beat(4)3
Avg EPS beat(4)50.47%
Min EPS beat(4)-32.66%
Max EPS beat(4)90.13%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-315.1%
EPS NQ rev (3m)-315.1%
EPS NY rev (1m)-6.75%
EPS NY rev (3m)-6.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-93.1%
Revenue NY rev (3m)-93.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2638.07
P/FCF N/A
P/OCF N/A
P/B 4.02
P/tB 4.03
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)-4.18
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -98.94%
ROE -132.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.65%
Cap/Sales 678.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -5.68
F-Score2
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)62.13%
Cap/Depr(5y)245.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-252.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.8%
EPS Next Y-58.23%
EPS Next 2Y-17.34%
EPS Next 3Y-26.11%
EPS Next 5Y13.09%
Revenue 1Y (TTM)-99.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1569.23%
Revenue Next 2Y1500.27%
Revenue Next 3Y716.2%
Revenue Next 5Y209.21%
EBIT growth 1Y-183.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.86%
OCF growth 3YN/A
OCF growth 5YN/A

CONNECT BIOPHARMA HOLDINGS L / CNTB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CONNECT BIOPHARMA HOLDINGS L?

ChartMill assigns a fundamental rating of 2 / 10 to CNTB.


What is the valuation status for CNTB stock?

ChartMill assigns a valuation rating of 0 / 10 to CONNECT BIOPHARMA HOLDINGS L (CNTB). This can be considered as Overvalued.


How profitable is CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a profitability rating of 0 / 10.


Can you provide the financial health for CNTB stock?

The financial health rating of CONNECT BIOPHARMA HOLDINGS L (CNTB) is 6 / 10.